Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Two-year effects of tirzepatide on glycemic control and body weight (SURPASS-5)
Contraindications include copper metabolism disorders (such as Wilsons disease), pregnancy, breastfeeding, or active infections
Hirahashi T et al
In clinical trials, participants lost an average of 14.9% of their body weight over 68 weeks (published in the New England Journal of Medicine)
The medication works by enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system pathways
It is a strong option when you want effective appetite support, a more familiar medication, and a treatment that feels steady and manageable
US$ 20.54
US$ 28.71
US$ 23.28
